Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T2rev
- Development stage
- Discontinued
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
T2rev (also known as v1003) is a reformulated transdermal patch formulation of buprenorphine developed by Grünenthal for the treatment of severe and persistent pain. Buprenorphine is a centrally acting opioid analgesic that acts as a partial agonist at the mu-type opioid receptor and an antagonist at the kappa-type opioid receptor. T2rev was designed as a low-dose alternative to the reference patch Transtec® PRO (70 µg/h), containing 13 mg of buprenorphine compared to the reference's 40 mg, while aiming to achieve bioequivalent plasma levels. The formulation was evaluated in Phase 1 single-dose and multiple-dose bioequivalence studies in healthy volunteers to assess its pharmacokinetic profile, safety, tolerability, and adhesiveness.
- Other names
- Patch with centrally acting analgesicbuprenorphine transdermal patch
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on T2rev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T2rev.